Education
Associate Professor Dr. Lisa Derosa’s educational journey is marked by a series of prestigious degrees and certifications. In 2023, she became an Associate Professor of Immunology at Paris-Saclay University in France. Prior to that, in 2019, she earned her PhD in Immunology from Paris-Sud University and registered as a physician in France the same year. She also obtained a University Diploma in Animal Experimentation Level 1 from Sorbonne University, Paris, in 2018. Her earlier academic achievements include a Diplôme Universitaire Européen de Recherche Translationnelle Et Clinique en Cancérologie (DUERTECC) from Paris-Sud University and a Diplôme d’Université Carcinologie Clíniques (DUC) from Université Paris XI, both in 2016. Dr. Derosa completed her M2 in Pharmacology, Clinical Trial in Oncology at Pisa University in Italy in 2015 and became Board Certified in Medical Oncology from the same university in 2014. She first qualified as a physician in Italy in 2009, following her MD from the School of Medicine at Pisa University in 2008.
Professional Experience
Associate Professor Dr. Lisa Derosa has a distinguished career in medical oncology and cancer immunology. Since 2022, she has been serving as the Co-Coordinator of the RHU IMMUNOLIFE (PIA2) multi-team program project in France and as a member of the Scientific Advisory Board for everImmune. In the same year, she was appointed as an Associate Professor of Immunology at Paris-Saclay University and a Senior Research Associate in the Cancer Immunology Department at Gustave Roussy Cancer Center (GRCC). Dr. Derosa has also been the Clinical Director of the ClinicoBiome Program at GRCC since 2020 and has held the position of Medical Oncology Specialist at GRCC since 2020. From 2017 to 2021, she co-coordinated the PIA2 RHU TORINO LUMIERE project. She has also been a Co-Coordinator of the H2020 ONCOBIOME project since 2019. Prior to these roles, Dr. Derosa served as a clinical attending in the Genitourinary and Lung Department at GRCC from 2019 to 2020 and completed a clinical fellowship in the Genitourinary Medical Oncology Department at GRCC from 2016 to 2019. Before joining GRCC, she was a clinical attending in the Oncology Department at Hospital S. Chiara-Pisa from 2014 to 2016. Additionally, she gained valuable experience as a visiting student at GRCC in 2013 and at the Oncology Department at Ospedali Riuniti di Livorno from 2006 to 2008.
Award and Honors
Associate Professor Dr. Lisa Derosa has received numerous prestigious awards and honors throughout her career, reflecting her significant contributions to oncology and immunology. In 2023, she was honored with the Conquer Cancer Foundation ASCO Merit Award. The previous year, she received an accolade from the European Society for Medical Oncology (ESMO) at their Asia Annual Meeting. In 2021, she was awarded the Best Scientific Paper published on Fundamental Research by European Urology and also received the ASCO Merit Award in Lung Cancer, supported by Frances A. Shepherd. Her exceptional work earned her the EATI Award in 2020. The year 2018 was particularly notable, as she received the Best Paper Award from ESMO YOC, the ESMO Annual Meeting Award, the Early Detection of Cancer Conference Award from ARC, and the Conquer Cancer Foundation ASCO Merit Award. In 2017, she was recognized with multiple Conquer Cancer Foundation ASCO Merit Awards, including the Genitourinary Cancer Merit Award. In 2016, she was the recipient of the 5th Pieter de Mulder Memorial Prize and the ESMO Translational Research Fellowship Award. Her early career was distinguished by the AIOM Award for young researchers in Oncology in 2015, the ESMO Annual Meeting Award in 2014, and the ITT Stage in Oncology Award from the Istituto Toscano Tumori in 2013.
Research Interest
Associate Professor Dr. Lisa Derosa’s research interests lie at the intersection of tumor immunology and cancer immunotherapy, with a particular focus on the immunosuppressive role of antibiotics in cancer treatment and the impact of gut microbiota on antitumor immunity. Since 2016, she has been pioneering research in these areas, exploring how the composition of gut microbiota can regulate the effectiveness of immune checkpoint inhibitors. Her innovative work has led to significant insights into the microbiota’s role in cancer treatment, making her a leading figure in the development of microbiota-centered interventions. Dr. Derosa currently directs the Microbiota-Centered Intervention Program (ClinicoBiome) at Gustave Roussy Cancer Center and co-directs the RHU Clinical Program Grant “Immunolife” as well as the EU Program Grant “Oncobiome.” Her research continues to bridge clinical oncology with translational research, aiming to improve patient outcomes through a deeper understanding of the immune system’s interactions with cancer therapies.
Research Skills
Associate Professor Dr. Lisa Derosa possesses a comprehensive skill set in the field of cancer immunology and immunotherapy, characterized by her expertise in clinical and translational research. She has extensive experience in designing and conducting clinical trials, particularly those investigating the interactions between gut microbiota and immune checkpoint inhibitors. Dr. Derosa is skilled in metagenomic analysis, allowing her to identify microbiome-based biomarkers that predict patient response to immunotherapy. Her proficiency in immunological assays and molecular biology techniques has been instrumental in her research on the immunosuppressive effects of antibiotics and the regulatory role of gut microbiota in antitumor immunity. Additionally, she has a strong background in pharmacodynamic and pharmacokinetic studies, which she has applied in various phase II clinical trials. Dr. Derosa’s ability to integrate clinical data with cutting-edge laboratory research has made her a leader in the development of microbiota-centered cancer therapies. Her collaborative projects often involve multidisciplinary teams, highlighting her skills in project management and scientific communication.